



Theraclion announces world's largest & first Asian study demonstrating benign thyroid nodule treatment efficacy with echotherapy

- *Median volume reduction of 68.3% at six months follow-up in 73-patient cohort*
- *Single treatment session treatment sufficient for ablation*
- *Minimal post-operative pain*
- *Published in American Thyroid Association (ATA)'s official journal, Thyroid*

Malakoff - FRANCE, March 7, 2017, 6pm CET - THERACLION (Alternext, FR0010120402 - ALTHE, PEA PME eligible), a company specialized in cutting-edge medical equipment for echotherapy, announced the publication of an asian study demonstrating that echotherapy using Echopulse® significantly reduces the size of large benign thyroid nodules. The study, entitled "[Single-session high intensity focus ultrasound \(HIFU\) treatment in large-sized benign thyroid nodules](#)" was published online on March 2, 2017 in the American Thyroid Association (ATA)'s official peer-reviewed journal, *Thyroid*.

The open-label, 73-patient study evaluated the efficacy of a single treatment of ultrasound-guided HIFU ablation employing the Echopulse® echotherapy system to treat small to large-sized benign thyroid nodules. Patients were divided into three groups depending on nodule size: small nodules <10 mL (Group 1), medium nodules between 10-30 mL (Group 2) and large nodules >30 mL (Group 3). The primary endpoint was nodule volume at six months with ablation success defined as more than a 50% reduction in nodule volume. Overall median volume reduction at six months was 68.3%. The treatment was well-tolerated with no reported serious side effects.

Professor Brian Lang, MD, The University of Hong Kong and principal investigator of this study, commented: *"This study demonstrated that echotherapy is effective and safe on a wide range of predominantly-solid benign thyroid nodules with encouraging volume reductions at six months. These results demonstrated a very feasible alternative to conventional thyroid surgery, with significant reduction in nodule volume after just single-session treatment."*

David Caumartin, CEO of Theraclion added: *"The size and density of the nodule has historically limited the effectiveness of echotherapy treatment. However, the BEAMOTION software introduced in early 2016 has enabled a much faster and focused treatment, making it possible to effectively treat large nodules. This is the first publication that provides the scientific evidence that echotherapy treats small-to-large thyroid nodules".*

"It is also the first publication on an Asian population, a geography, with China and Korea at the forefront, that we anticipate will be one of our biggest market in the near future," **concluded Sylvain Yon, Deputy CEO, Theraclion.**

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com

Theraclion is listed on Alternext Paris

PEA-PME eligible

Mnemonic: ALTHE - ISIN Code: FR0010120402



Contact:

Theraclion

David Caumartin
Chief Executive Officer
Tel.: +33 (0)1 55 48 90 70
david.caumartin@theraclion.com

NewCap

Financial Communication and Investor Relations
Emmanuel Huynh / Valentine Brouchet
Tel.: +33 (0)1 44 71 94 94
theraclion@newcap.eu

Kalima

Press Relations
Florence Calba
Tel.: + 33 (0)1 44 90 82 54
fcalba@kalima-rp.fr

The Ruth Group (U.S.)

Investor Relations / Public Relations
Robert Flamm / Kirsten Thomas
+1 646-536-7017 / +1 508-280-6592
rflamm@theruthgroup.com / thomas@theruthgroup.com